<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Substance use disorder in adolescents: Epidemiology, clinical features, assessment, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Substance use disorder in adolescents: Epidemiology, clinical features, assessment, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Substance use disorder in adolescents: Epidemiology, clinical features, assessment, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oscar Bukstein, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22982052"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Substance use is pervasive and endemic among adolescents. By the time adolescents become adults in the United States, almost half will have tried an illicit drug, and over 80 percent will have used alcohol [<a href="#rid1">1</a>]. Most use by adolescents will attenuate over time, but many suffer negative health and social consequences [<a href="#rid2">2</a>]. Some adolescents advance to levels of use and consequences that meet criteria for substance use disorders (SUDs) and are at high risk for its continuation in adulthood.</p><p>The general approach to the assessment and treatment of adolescents with SUDs is similar in some respects to adults; however, developmental considerations require an approach tailored to the cognitive, social, and legal status of adolescents.</p><p>The epidemiology, pathogenesis, clinical features, screening, and diagnosis of substance use and SUD in adolescents are reviewed here. Treatment for SUD in adolescents is described separately, as is tobacco prevention and cessation management in adolescents. (See  <a class="medical medical_review" href="/z/d/html/108256.html" rel="external">"Substance use disorder in adolescents: Psychosocial management"</a> and  <a class="medical medical_review" href="/z/d/html/14583.html" rel="external">"Prevention of smoking and vaping initiation in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6359.html" rel="external">"Management of smoking and vaping cessation in adolescents"</a>.)</p><p class="headingAnchor" id="H22982058"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Substance use is pervasive and endemic among adolescents in the United States, European countries, and other countries  (<a class="graphic graphic_table graphicRef110064" href="/z/d/graphic/110064.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H22982066"><span class="h2">Alcohol use</span><span class="headingEndMark"> — </span>The prevalence of alcohol use varies. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>According to a European School Survey Project on Alcohol and Other Drugs, 34 percent of female and 36 percent of male European students reported heavy episodic drinking [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the National Survey on Drug Use and Health (NSDUH), 3.8 percent of persons in the United States age 12 to 17 years reported past month binge drinking [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estimates of binge monthly alcohol use and heavy monthly alcohol use in the past month among youth age 12 to 20 years old were 1.6 percent and 8.3 percent respectively [<a href="#rid4">4</a>].</p><p></p><p>Binge drinking, defined as three to five or more drinks per occasion [<a href="#rid5">5</a>], is associated with 4300 deaths among underage youth each year, as well as school, social, and physical problems in adolescents [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H697433122"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for problematic drinking and binge drinking in adolescents overlap broadly with risk factors for the use of other recreational drugs (see <a class="local">'Risk factors'</a> below). One prospective cohort study found that parental supply of sips or whole drinks of alcohol to adolescents was associated with increased odds of binge drinking (odds ratio 1.85, 99.5% CI 1.17-2.91) and alcohol-related harms (odds ratio 1.70, 99.5% CI 1.20-2.42) [<a href="#rid7">7</a>].</p><p>Solitary drinking, compared with only social drinking, is also a risk factor for alcohol-related problems in adolescents and young adults. A meta-analysis of 21 studies showed increased risk of alcohol use disorder and academic, legal, interpersonal, emotional, and physical health problems among adolescents who reported solitary drinking [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H22982074"><span class="h2">Drug use</span></p><p class="bulletIndent1"><span class="glyph">●</span>Substantial proportions of youth surveyed had tried illicit drugs at least once in their lifetime in the countries that follow [<a href="#rid1">1,4,9,10</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Australia – Greater than 40 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Canada – 60 percent </p><p class="bulletIndent2"><span class="glyph">•</span>Europe – 19 percent of boys, 14 percent of girls</p><p class="bulletIndent2"><span class="glyph">•</span>United States – Greater than 40 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>16.6 percent of 8<sup>th</sup> graders</p><p class="bulletIndent3"><span class="glyph">-</span>41.0 percent of 12<sup>th</sup> graders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>6.3 percent of 12<sup>th</sup> graders in the United States reported smoking marijuana daily, and one in seven reported having been a daily marijuana smoker at some time for at least a month [<a href="#rid1">1</a>]. 13.6 percent of high school adolescents reported marijuana use in the past month.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>According to a survey project, the rate of cannabis use among European youth age 12 to 17 in the past month was 13 percent [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H22982081"><span class="h2">Substance use disorders</span><span class="headingEndMark"> — </span>A study of a nationally representative sample of United States adolescents in the National Comorbidity Study estimated the lifetime prevalence of any substance use disorder to be 11.4 percent [<a href="#rid11">11</a>]. According to the NSDUH study, 8.5 percent of adolescents age 12 to 17 had an SUD [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Illicit drugs </strong>– Epidemiologic studies in the United States estimated a lifetime prevalence of SUDs for illicit drugs in adolescents to be between 4.0 and 8.9 percent [<a href="#rid12">12</a>]. Studies of the lifetime prevalence of SUD for illicit drugs in select age groups in the United States include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>3.4 percent prevalence of SUD for illicit drugs in youth age 13 to 14 years [<a href="#rid12">12</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>16.5 percent prevalence of SUD for illicit drugs in youth age 17 to 18 years [<a href="#rid12">12</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol</strong> – Epidemiologic studies in the United States estimated that the lifetime prevalence of alcohol use disorders is between 3.4 and 6.4 percent in adolescents as a whole [<a href="#rid13">13</a>]. Findings in selected subgroups included [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1.3 percent in adolescents age 13 to 14</p><p class="bulletIndent2"><span class="glyph">•</span>15.1 percent of adolescents age 17 to 18</p><p></p><p class="headingAnchor" id="H22982089"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Multiple studies have found associations between early age of first alcohol or other substance use and the development of substance dependence [<a href="#rid14">14</a>]. Other risk factors for the development of substance use and SUDs include the individual, peer, family, and community characteristics below [<a href="#rid15">15-18</a>]. Most adolescents with early onset of substance use (eg, before age 13 to 14) or who develop SUDs usually have multiple risk factors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parental drug/alcohol use</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intrauterine exposure to drugs/alcohol</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Marital conflict</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family dysfunction/disturbed family environment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parental favorable attitudes toward alcohol and/or drug use</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Substance use among siblings</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Negative life events</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor parenting – Rejection, lack of parental warmth, parent-child conflict, parental hostility/low attachment, harsh discipline, lack of or inconsistent discipline, permissive parenting, inadequate supervision and monitoring, child abuse/maltreatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individual risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Difficult temperament/inflexibility, depression, withdrawal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irritability</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Motor, language, and cognitive impairments</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early aggressive behavior</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor social skills: impulsive, aggressive, passive, and withdrawn</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor social problem-solving skills</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensation seeking</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of behavioral self-control</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early persistent behavior problems/antisocial behavior</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attention deficit hyperactivity disorder (ADHD)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor impulse control/impulsivity, poor concentration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low self-esteem, perceived incompetence, negative explanatory, and inferential style</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor grades/achievements/school failure, low commitment to school</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tobacco use, cannabis use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peer risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deviant peer group</p><p class="bulletIndent2"><span class="glyph">•</span>Peer attitudes toward drugs</p><p class="bulletIndent2"><span class="glyph">•</span>Decrease in social support accompanying entry into a new social context</p><p class="bulletIndent2"><span class="glyph">•</span>Attending college</p><p class="bulletIndent2"><span class="glyph">•</span>Substance-using peers</p><p class="bulletIndent2"><span class="glyph">•</span>Social adversity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laws and norms favorable toward alcohol and drug use</p><p class="bulletIndent2"><span class="glyph">•</span>Availability and access to alcohol</p><p class="bulletIndent2"><span class="glyph">•</span>Urban setting</p><p class="bulletIndent2"><span class="glyph">•</span>Poverty</p><p class="bulletIndent2"><span class="glyph">•</span>Community/school violence</p><p></p><p class="headingAnchor" id="H22982113"><span class="h2">Co-occurring disorders</span><span class="headingEndMark"> — </span>In studies of youth 13 to 18 years of age with a mental disorder, rates of a co-occurring SUD have ranged from 61 to 88 percent [<a href="#rid19">19,20</a>]. In a community-based epidemiologic study that included 10,123 adolescents age 13 to 18 years, three times as many adolescents with a current SUD, compared with those without an SUD, had a current co-occurring mental disorder [<a href="#rid21">21</a>]. Co-occurring mental disorders among adolescent youth (12 to 18 years) with substance use or a substance use disorder include:</p><p class="bulletIndent1"><span class="glyph">●</span>Conduct disorder</p><p class="bulletIndent1"><span class="glyph">●</span>ADHD</p><p class="bulletIndent1"><span class="glyph">●</span>Major depressive disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Disruptive mood dysregulation disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Posttraumatic stress disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Schizophrenia</p><p></p><p>Other relevant findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of mood disorders, such as bipolar, is often preceded by cannabis use [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suicide is closely associated with substance use [<a href="#rid23">23,24</a>]. Many psychiatric disorders that are comorbid with SUDs carry an increased risk of suicidal behavior. Substance use may increase the risk for suicidal behavior, as substance intoxication may decrease judgment and increase dysphoria and impulsivity due to direct pharmacologic effects. Substance use may also lead to suicidal behavior by increasing stress and exacerbate co-occurring psychiatric disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-five to 50 percent of adolescents with conduct disorder or oppositional defiant disorder have been found to have an SUD [<a href="#rid25">25</a>]. Over half of adolescents with SUDs have been found to have co-occurring conduct disorder and/or oppositional defiant disorder. The two conditions have a reciprocal relationship: Conduct disorder is associated with increased substance use, and substance use worsens conduct disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 20 to 27 percent of adolescents with an SUD have comorbid ADHD [<a href="#rid26">26</a>].</p><p></p><p>Relative to substance use, co-occurring mental disorders may [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Precede as a risk factor</p><p class="bulletIndent1"><span class="glyph">●</span>Develop as a consequence</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate the severity</p><p class="bulletIndent1"><span class="glyph">●</span>Originate from a common vulnerability as SUDs</p><p></p><p class="headingAnchor" id="H22982119"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>There are strong environmental and genetic risk factors for the development of SUDs. Adoption, twin, and extended-family studies have established the genetic or heritable component of predisposition to tobacco, alcohol, and illicit drug use disorder. Shared environmental influences are relatively stronger at earlier stages of substance involvement (initiation and use) [<a href="#rid28">28,29</a>]. There is considerable overlap in the genetic influences associated with SUDs across drug classes, and shared genetic influences contribute to the commonly observed associations between SUDs and externalizing disorders [<a href="#rid29">29</a>].</p><p>As with most behavioral and psychiatric disorders, the interplay between genetic risk, temperamental traits, and the environment may predispose specific youth to early use of substances and persistent substance use. Once exposed to substances, brain reward systems reinforce substance use, resulting in repeated use and lower ability to control substance use. As the adolescent brain has not fully matured, the effects of substances on the reward system predispose to more profound effects of substance use compared with older age at initiation of use.</p><p>This research supports an etiologic model of individual differences in substance use, in which initiation and early patterns of use are strongly influenced by social and familial environmental factors, while later levels of use are strongly influenced by genetic factors.</p><p class="headingAnchor" id="H22982125"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Acute pharmacologic effects of alcohol and/or drug use in adolescents include changes in mood, perception, cognition, and psychomotor performance.</p><p>Chronic physical manifestations of substance use are rarely noted during adolescents due to the relative brief duration of their use careers. Polysubstance use by adolescents appears to be a rule rather than the exception.</p><p>SUD can be distinguished from substance use by the presence of psychosocial impairment and behaviors related to obtaining, using, or recovering from the substance. For most adolescents who try substances, especially alcohol and marijuana, sporadic or low frequency substance use often does not result in an SUD [<a href="#rid2">2</a>].</p><p>SUDs should be considered in an adolescent patient with psychosocial problems and/or impairment, although these could be the result of comorbid conditions or due to risk factors that predispose individuals for the development of SUDs. (See <a class="local">'Risk factors'</a> above.)</p><p>Psychosocial problems caused by substance use in adolescents are typically related to family, peer, legal, work, and/or school factors, or to use in physically hazardous situations. Salient use behaviors connote a substantial level of involvement with substance use (eg, tolerance and/or withdrawal), compulsive use (ie, often taken in larger amounts or over a longer period than intended, or a great deal of time is spent to obtain substance or recover from its effects), use with disregard or minimization of consequences of impairment, and/or use to the exclusion of other important activities or role obligations. Continued use despite recurrent problems related to use is also a common manifestation of SUDs. (See <a class="local">'DSM-5-TR diagnostic criteria'</a> below.)</p><p>The clinical manifestations of SUDs in adolescents differ in several respects from SUDs in adults. This is primarily due to adolescents’ earlier stage of development, shorter duration of substance use, and the types of impairment seen [<a href="#rid25">25</a>]. Adults have had a longer duration in which to develop chronic health effects and more opportunities to use substances regularly without the interference of family or school. Adults can purchase alcohol, which adolescents cannot legally do.</p><p>Withdrawal symptoms due to alcohol are uncommon in adolescents; however, other problems related to high blood alcohol levels such as “black outs” occasionally occur. Substance intoxication may lead to episodes of aggressive behavior, unplanned sexual behavior with questions of consent, and other maladaptive social behavior manifesting poor judgement.</p><p class="headingAnchor" id="H22982131"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>Most adolescents who try alcohol or other drugs do not develop SUDs. As an example, approximately 9 percent of cannabis users have been found to develop cannabis use disorder, a rate that increases among those who start young (to approximately 17 percent) and among daily users (to 25 to 50 percent) [<a href="#rid30">30</a>]. Cannabis use is associated with increased rates of illicit drug use [<a href="#rid31">31</a>]. Other relevant findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>Earlier onset of alcohol use is associated with a more rapid development of dependence and with worse outcomes [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescence is a period of development associated with major risk for developing an SUD; the median onset of an SUD is 15 years old [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescent substance use predicts employment problems, other substance use disorder, and criminal and violent behavior [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H22982137"><span class="h1">CLINICAL CONSEQUENCES</span><span class="headingEndMark"> — </span>Substance use and/or SUDs are associated with a number of negative consequences among youth, including accidents, death, hazardous behaviors, health effects, crime, increased sexual behaviors and unplanned pregnancy, and lower achievement [<a href="#rid35">35-37</a>].</p><p class="headingAnchor" id="H2043701831"><span class="h2">Cannabis, cannabidiol, and synthetic cannabinoids</span><span class="headingEndMark"> — </span>Cannabis use in adolescence, a time of brain development, is associated with reduced intelligence quotient (IQ), decreased neural connectivity, increased risks of depression, suicidality, and psychosis in young adulthood, and may be associated with cognitive impairment. The use of cannabidiol or synthetic cannabinoids also appear to be associated with mental health disorders [<a href="#rid38">38</a>]. Adolescents (and younger children) should be advised to avoid cannabis consumption.</p><p class="bulletIndent1"><span class="glyph">●</span>Cannabis-related neurocognitive deficits in attention and memory that persist beyond abstinence suggest possible structural brain alterations (eg, changes in gray matter tissue), changes in white matter tract integrity, and abnormalities of neural functioning (eg, increased brain activation) [<a href="#rid39">39</a>]. However, it remains difficult to determine whether reported group differences reflect pre-existing brain differences that may increase the risk for substance use and risk-taking behaviors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis found adolescent cannabis use to be associated with increased risks of depression and suicidality in young adulthood [<a href="#rid40">40</a>]. The analysis of 11 prospective longitudinal studies with 23,317 individuals age 18 and younger found increased risks of depression (odds ratio 1.37, 95% CI 1.16-1.62), suicidal ideation (odds ratio 1.50, 95% CI 1.11-2.03), and suicidal attempt (odds ratio 3.46, 95% CI 1.53-7.84) between the age of 18 to 32 years.</p><p></p><p class="bulletIndent1">In a survey of 6672 adolescents from the United Kingdom, the use of cannabis, cannabidiol, and synthetic cannabinoid were each associated with increased likelihood of the development of probable depressive disorder, probable generalized anxiety disorder, probable conduct disorder, and the presence of auditory hallucinations [<a href="#rid38">38</a>]. For each disorder, the risk appeared to be greatest with synthetic cannabinoid use; however, study design limits causal interpretation. Further studies with stronger study designs are suggested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis also found 3.9-fold increased risk for the development of psychosis after cannabis use, with a strong relationship reported between cannabis use between age 15 to 18 and eventual emergence of psychosis [<a href="#rid41">41</a>].</p><p></p><p>The relationship between cannabis use, medical and psychiatric comorbidities, and other adverse health consequences is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p class="headingAnchor" id="H2808800888"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Our approach is consistent with the guidelines from the American Academy of Pediatrics Screening which recommends screening for an adolescent’s use of alcohol, tobacco, and other drugs annually, typically beginning at age 11 years [<a href="#rid42">42-44</a>]. (See  <a class="medical medical_review" href="/z/d/html/2872.html" rel="external">"Screening tests in children and adolescents", section on 'Nicotine, alcohol, and substance use'</a>.)</p><p>Screening is a process in which adolescents are identified according to characteristics indicating that they possibly have a problem with substance use. Screening is appropriate for nonclinical settings, such as schools, as well as clinical settings, such as primary care and non-SUD specialty mental health. Screening does not provide information about the severity of an adolescent’s substance use or the presence of an SUD. A positive screening result identifies the need<strong> </strong>for a comprehensive substance use assessment and based on the results, possible need for treatment. Screening is part of the assessment but does not render a diagnosis.</p><p>AAP guidelines suggest using the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thenationalcouncil.org%2Fprogram%2Fcenter-of-excellence%2F&amp;token=ht%2BscX9Xg1qM5nMXlH6J9EleVzvMx05nhN1Op1aA40beF2x9%2FWfsdI0%2BaZkBgnnJrS0itYE7UbdXn4CxoHN%2FN6vsl6hC7ZaY63%2FAuzVRMd0%3D&amp;TOPIC_ID=101699" target="_blank">CRAFFT screen</a> to identify problematic substance use. The CRAFFT screen is a brief screening tool that has been validated in the adolescent primary care setting [<a href="#rid45">45-47</a>]. The six CRAFFT screening questions are asked if the adolescent endorses drinking alcohol, smoking marijuana or hashish, vaping tobacco or other products, or using any other substance to get high during the previous 12 months. Two or more positive answers indicate a positive screen:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C</strong> – Have you ever ridden in a <strong>Car</strong> driven by someone (including self) who was high, drunk, or had been using drugs?</p><p class="bulletIndent1"><span class="glyph">●</span><strong>R</strong> – Have you ever used drugs or alcohol to <strong>Relax</strong>?</p><p class="bulletIndent1"><span class="glyph">●</span><strong>A</strong> – Do you ever use <strong>Alone</strong>? </p><p class="bulletIndent1"><span class="glyph">●</span><strong>F</strong> – Do you ever <strong>Forget</strong> things that you did while using?</p><p class="bulletIndent1"><span class="glyph">●</span><strong>F</strong> – Do <strong>Family or Friends</strong> tell you to cut down?</p><p class="bulletIndent1"><span class="glyph">●</span><strong>T</strong> – Have you ever gotten into <strong>Trouble </strong>when using?</p><p></p><p>The United States National Institute on Alcohol Abuse and Alcoholism (NIAAA) recommends that clinicians ask children age 9 to 11 and adolescents 11 to 14, two questions about alcohol use [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>“Do you have any friends who drank beer, wine, or any drink containing alcohol in the past year?”</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Followed by: “How about you – in the past year, on how many days have you had more than a few sips of beer, wine, or any drink containing alcohol?”</p><p></p><p>For the younger youth, less than 14 years of age, any drinking is cause for concern. Older teens, age 14 to 18, should be asked the questions in the reverse order, with higher amounts indicating higher levels of risk:</p><p class="bulletIndent1"><span class="glyph">●</span>“In the past year, on how many days have you had more than a few sips of beer, wine, or any drink containing alcohol?”</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>“If your friends drink, how many drinks do they usually drink on an occasion?”</p><p></p><p>Two other screeners have satisfactory psychometrics and can be used similar to the CRAFFT, especially in primary care offices.</p><p class="bulletIndent1"><span class="glyph">●</span>The Screening to Brief Intervention (S2BI) instrument is an instrument that can be administered digitally and can reveal the frequency of past-year use of tobacco, alcohol, marijuana, and five other classes of substances most commonly used by adolescents [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Brief Screener for Tobacco, Alcohol, and other Drugs uses highly sensitive and specific cutoffs to identify various SUDs among adolescents 12 to 17 years of age: ≥6 days of past-year use for tobacco and &gt;1 day of past-year use for alcohol or marijuana [<a href="#rid50">50</a>].</p><p></p><p>Although specific interview questions with established validity such as the NIAAA screening systems, CRAFFT, or S2BI are often sufficient for screening in the emergency room or primary care setting [<a href="#rid51">51,52</a>], many clinicians use specific screening instruments such as the Alcohol Use Disorders Identification Test or Drug Abuse Screening Test [<a href="#rid53">53</a>]. Due to high rates of co-occurring SUD in adolescents with mental disorders, a more comprehensive substance use assessment is favored in mental health specialty settings. (See  <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a>.)</p><p>In addition to interview questions and screening instruments, the identification of specific risk factors can prompt performance of or referral for a comprehensive assessment, even in the absence of an adolescent’s report of regular use or consequences. Such risk factors include a past history of substance use, high-risk behaviors, or moderate to severe high-risk status. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H22982255"><span class="h1">ASSESSMENT</span><span class="headingEndMark"> — </span>A comprehensive substance use assessment is a thorough process that includes variables or factors contributing to and maintaining substance use disorder, the severity of substance-related problems, and the variety of consequences associated with the adolescent’s substance use. (See  <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a>.)</p><p>The assessment process is used to identify those individuals who meet the diagnostic criteria for an SUD diagnosis, and to determine its severity from the quantity and frequency of use, the substances used, the presence of specific substance use behaviors, the pattern of use, and any consequences of use. The results of a comprehensive assessment will usually identify which individuals require treatment, what level of treatment, and other problems, as well as strengths of the adolescent that may be helpful during treatment.</p><p>A comprehensive evaluation requires assessment of many domains of functioning in the adolescent’s life. These domains include [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Substance use behaviors and disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric and behavioral problems</p><p class="bulletIndent1"><span class="glyph">●</span>School and occupational functioning</p><p class="bulletIndent1"><span class="glyph">●</span>Family functioning</p><p class="bulletIndent1"><span class="glyph">●</span>Peer relations and social competency</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to trauma, maltreatment or abuse</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual and gender identity</p><p class="bulletIndent1"><span class="glyph">●</span>Leisure/recreation</p><p></p><p class="headingAnchor" id="H1861850157"><span class="h2">Toxicology</span><span class="headingEndMark"> — </span>Toxicologic tests or drug screens of bodily fluids (usually urine but also saliva) and of hair samples detect the presence of specific substances. The basic drug screen used consistently across the United States tests for amphetamines, cocaine, cannabis, opioids, and phencyclidine. Many drug screens used outside the United States omit phencyclidine but include tests for benzodiazepines and a wider range of opioids. Individual tests are available for other drugs, including alcohol. (See  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p>A formal substance use examination by an addictions specialist or psychiatrist should include such testing. Continuing care for an adolescent with an SUD with a goal of maintaining abstinence should include intermittent random urine screening. Primary care clinicians do not routinely use drug screens but may, particularly when the clinician is part of a more comprehensive treatment team and has consent from the adolescent.</p><p>Urine screening optimally includes proper collection techniques, evaluation of positive results, and specific plan(s) of action should the specimen be positive or negative. There are mixed views regarding whether sample collection from an adolescent should be monitored. Prior to testing, the clinician should establish rules regarding the confidentiality of the results.</p><p>A positive specimen indicates only the presence of specific drug(s) and not necessarily the presence of an SUD or a specific pattern of use. Because of the limited time a drug will remain in the urine and possible adulteration, a negative urine screen does not definitively indicate that the adolescent does not use drugs.</p><p class="headingAnchor" id="H22982261"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) conceptualizes the prior constructs of substance use and substance dependence as a single entity substance use disorder [<a href="#rid55">55</a>]:</p><p>A specifier indicates severity (See <a class="local">'Severity'</a> below.)</p><p class="headingAnchor" id="H2579631926"><span class="h2">DSM-5-TR diagnostic criteria</span><span class="headingEndMark"> — </span>DSM-5-TR diagnostic criteria for SUD are described below [<a href="#rid55">55</a>].</p><p>A problematic pattern of use leading to clinically significant impairment or distress is manifested by two or more of the following within a 12-month period:</p><p class="bulletIndent1"><span class="glyph">●</span>1. Often taken in larger amounts or over a longer period than was intended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>2. A persistent desire or unsuccessful efforts to cut down or control use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>3. A great deal of time is spent in activities necessary to obtain, use, or recover from the substance’s effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>4. Craving or a strong desire or urge to use the substance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5. Recurrent use resulting in a failure to fulfill major role obligations at work, school, or home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>6. Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by its effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>7. Important social, occupational, or recreational activities are given up or reduced because of use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>8. Recurrent use in situations in which it is physically hazardous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>10. Tolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>11. Withdrawal.</p><p></p><p>Applying these criteria to adolescents requires consideration of the developmental context. As an example, adolescents with alcohol use disorder commonly exhibit tolerance (ie, requiring increasing amounts of a substance to achieve the same effect), but less frequently show withdrawal or other symptoms of physiologic dependence [<a href="#rid55">55</a>]. Many adolescents with cannabis and opioid use disorders manifest withdrawal symptoms [<a href="#rid55">55</a>].</p><p>Preoccupation with use is often demonstrated by giving up previously important activities, increasing the time spent in activities related to substance use, and using more frequently or for longer amounts of time than planned. An adolescent may use despite the continued existence or worsening of problems caused by substance use. In applying criteria on consequences and behaviors associated with use, it is important to include alcohol-related blackouts, craving, and impulsive sexual behavior.</p><p class="headingAnchor" id="H1617329092"><span class="h3">Severity</span><span class="headingEndMark"> — </span>The severity of an SUD at the time of diagnosis can be specified as a subtype based on the number of DSM-5-TR criteria present:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Two to three criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Four to five criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Six or more criteria</p><p></p><p class="headingAnchor" id="H2595582733"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Substance use is pervasive and endemic among adolescents in the United States and many other countries. By the time adolescents become adults in the United States, almost half will have tried an illicit drug, and over 80 percent will have used alcohol. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-occurring disorders</strong> – Epidemiologic studies in the United States have found a significant prevalence of substance use disorders (SUDs) among adolescents, along with substantial rates of co-occurring mental disorders. (See <a class="local">'Substance use disorders'</a> above and <a class="local">'Co-occurring disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for the development of substance use and SUDs include individual, peer, family, and community characteristics. Adolescents with early onset of substance use/SUD (eg, prior to age 17 to 18 years) usually have multiple risk factors. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Research supports an etiologic model of individual differences in substance use, in which initiation and early patterns of use are strongly influenced by social and familial environmental factors, while later levels of use are strongly influenced by genetic factors. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Acute pharmacologic effects of alcohol and/or drug use in adolescents include changes in mood, perception, cognition, and psychomotor performance. Chronic physical and psychiatric manifestations of substance use are rare. Substance intoxication may lead to black-outs, aggressive behavior, unplanned sexual behavior, and other behaviors associated with poor judgement. (See <a class="local">'Clinical Features'</a> above.)</p><p></p><p class="bulletIndent1">SUD can be distinguished from substance use by the presence of psychosocial impairment and behaviors related to obtaining, using, or recovering from the substance. Most adolescents who try alcohol or other drugs do not develop SUDs. (See <a class="local">'Clinical Features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consequences</strong> – Substance use and/or SUDs are associated with a number of negative consequences among youth, including accidents, death, health effects, crime, unplanned pregnancy, and lower achievement. (See <a class="local">'Clinical consequences'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabis, cannabidiol, and synthetic cannabinoids </strong>– Cannabis use in adolescence, a time of brain development, is associated with reduced intelligence quotient (IQ), decreased neural connectivity, increased risks of depression, suicidality, and psychosis in young adulthood, and may be associated with cognitive impairment. Cannabidiol and synthetic cannabis each appear to be associated with possible mental health disorders. We advise adolescents (and younger children) to avoid cannabis consumption. (See <a class="local">'Cannabis, cannabidiol, and synthetic cannabinoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Our approach is consistent with the American Academy of Pediatrics (AAP) in the United States that recommends screening adolescents’ use of alcohol, tobacco, and other drugs annually, typically beginning at age 11 years. Guidelines for screening adolescents are described in detail separately. (See <a class="local">'Screening'</a> above and  <a class="medical medical_review" href="/z/d/html/2872.html" rel="external">"Screening tests in children and adolescents", section on 'Nicotine, alcohol, and substance use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong> – A comprehensive substance use assessment evaluates consumption, substance use behaviors, psychiatric and behavioral problems, school and occupational functioning, family functioning, social competency and peer relations, and leisure/recreation. Toxicology testing is typically part of a comprehensive assessment by an addictions specialist or psychiatrist, and random drug tests are a part of treatment with a goal of abstinence. (See <a class="local">'Assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnostic criteria for substance use disorder includes two or more of the listed criteria within a 12-month period. Severity is indicated by a modifier code.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Monitoring the Future national survey results on drug use, 1975–2022: Secondary school students. Monitoring the Future Monograph Series. Ann Arbor, MI: Institute for Social Research, University of Michigan. https://monitoringthefuture.org/wp-content/uploads/2022/12/mtf2022.pdf (Accessed on September 12, 2023).</li><li><a class="nounderline abstract_t">Chen K, Kandel DB. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health 1995; 85:41.</a></li><li class="breakAll">ESPAD Group (2020), ESPAD Report 2019: Results from the European School Survey Project on Alcohol and Other Drugs, EMCDDA Joint Publications, Publications Office of the European Union, Luxembourg http://www.espad.org/sites/espad.org/files/2020.3878_EN_04.pdf (Accessed on September 12, 2023).</li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. United States Department of Health and Human Services, Rockville, MD 2021.</li><li class="breakAll">National Institute of Alcohol Abuse and Alcoholism (NIAAA). NIAAA council approves definition of binge drinking, NIAAA Newsletter 2004. No. 3, p.3.</li><li class="breakAll">Centers for Disease Control and Prevention (CDC). Fact Sheets - Underage Drinking. http://www.cdc.gov/alcohol/fact-sheets/underage-drinking.htm (Accessed on July 14, 2016).</li><li><a class="nounderline abstract_t">Aiken A, Clare PJ, Boland VC, et al. Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. Drug Alcohol Depend 2020; 215:108204.</a></li><li><a class="nounderline abstract_t">Skrzynski CJ, Creswell KG. Associations between solitary drinking and increased alcohol consumption, alcohol problems, and drinking to cope motives in adolescents and young adults: a systematic review and meta-analysis. Addiction 2020; 115:1989.</a></li><li class="breakAll">The European school survey project on alcohol and other drugs. The 2011 ESPAD report. www.espad.org (Accessed on August 28, 2015).</li><li class="breakAll">Canadian Alcohol and Drugs Survey (CADS): summary of results for 2019 https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-survey/2019-summary.html (Accessed on September 12, 2023).</li><li><a class="nounderline abstract_t">Swendsen J, Burstein M, Case B, et al. Use and abuse of alcohol and illicit drugs in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement. Arch Gen Psychiatry 2012; 69:390.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795, Substance Abuse and Mental Health Administration; Health and Human Services, Rockville, MD 2013.</li><li class="breakAll">SAMSHA. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. www.samhsa.gov/data/sites/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf (Accessed on August 01, 2015).</li><li><a class="nounderline abstract_t">Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 2011; 115:120.</a></li><li><a class="nounderline abstract_t">Swedo EA, Sumner SA, de Fijter S, et al. Adolescent Opioid Misuse Attributable to Adverse Childhood Experiences. J Pediatr 2020; 224:102.</a></li><li class="breakAll">National Research Council (US) and Institute of Medicine (US) Research Advances and Promising Interventions. Preventing Mental Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities, O’Connell ME, Boat T, Warner KE (Eds), National Academies Press, Washington DC 2009.</li><li><a class="nounderline abstract_t">Griesler PC, Hu MC, Wall MM, Kandel DB. Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US. JAMA Netw Open 2021; 4:e2031073.</a></li><li><a class="nounderline abstract_t">Shanahan L, Hill SN, Bechtiger L, et al. Prevalence and Childhood Precursors of Opioid Use in the Early Decades of Life. JAMA Pediatr 2021; 175:276.</a></li><li><a class="nounderline abstract_t">Couwenbergh C, van den Brink W, Zwart K, et al. Comorbid psychopathology in adolescents and young adults treated for substance use disorders: a review. Eur Child Adolesc Psychiatry 2006; 15:319.</a></li><li><a class="nounderline abstract_t">Armstrong TD, Costello EJ. Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol 2002; 70:1224.</a></li><li><a class="nounderline abstract_t">Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49:980.</a></li><li><a class="nounderline abstract_t">Duffy A, Horrocks J, Milin R, et al. Adolescent substance use disorder during the early stages of bipolar disorder: a prospective high-risk study. J Affect Disord 2012; 142:57.</a></li><li><a class="nounderline abstract_t">Schilling EA, Aseltine RH Jr, Glanovsky JL, et al. Adolescent alcohol use, suicidal ideation, and suicide attempts. J Adolesc Health 2009; 44:335.</a></li><li><a class="nounderline abstract_t">Wong SS, Zhou B, Goebert D, Hishinuma ES. The risk of adolescent suicide across patterns of drug use: a nationally representative study of high school students in the United States from 1999 to 2009. Soc Psychiatry Psychiatr Epidemiol 2013; 48:1611.</a></li><li class="breakAll">Bukstein OG. Conduct disorder and delinquency and substance use disorders. In: Youth Substance Abuse and Co-Occurring Disorders, Kaminer Y (Ed), American Psychiatric Association Publishing, Washington DC 2015. p.81.</li><li><a class="nounderline abstract_t">van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 2012; 122:11.</a></li><li><a class="nounderline abstract_t">Hersh J, Curry JF, Kaminer Y. What is the impact of comorbid depression on adolescent substance abuse treatment? Subst Abus 2014; 35:364.</a></li><li><a class="nounderline abstract_t">Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry 2008; 65:674.</a></li><li><a class="nounderline abstract_t">Lynskey MT, Agrawal A, Heath AC. Genetically informative research on adolescent substance use: methods, findings, and challenges. J Am Acad Child Adolesc Psychiatry 2010; 49:1202.</a></li><li><a class="nounderline abstract_t">Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374:1383.</a></li><li class="breakAll">National Institute on Drug Abuse. Drug Facts: Nationwide Trends, 2014. www.drugabuse.gov/publications/drugfacts/nationwide-trends (Accessed on January 15, 2015).</li><li><a class="nounderline abstract_t">Grant BF, Stinson FS, Harford TC. Age at onset of alcohol use and DSM-IV alcohol abuse and dependence: a 12-year follow-up. J Subst Abuse 2001; 13:493.</a></li><li><a class="nounderline abstract_t">Merikangas RS, He J, Bustein M, et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Study-Adolescent Supplement (NCS-A). J Am Acad Child Psychiatry 2010; 49:980.</a></li><li><a class="nounderline abstract_t">Ellickson PL, Tucker JS, Klein DJ. Ten-year prospective study of public health problems associated with early drinking. Pediatrics 2003; 111:949.</a></li><li><a class="nounderline abstract_t">Tucker JS, Ellickson PL, Orlando M, et al. Substance use trajectories from early adolescence to emerging adulthood: A comparison of smoking, binge drinking, and marijuana use. J Drug Issues 2005; 35:307.</a></li><li><a class="nounderline abstract_t">Miller JW, Naimi TS, Brewer RD, Jones SE. Binge drinking and associated health risk behaviors among high school students. Pediatrics 2007; 119:76.</a></li><li class="breakAll">Centers for Disease Control and Prevention. (2012). Youth risk behavior surveillance--United States, 2011. Morbidity and Mortality Weekly Report, 61(4). http://www.cdc.gov/mmwr/pdf/ss/ss6104.pdf (Accessed on September 27, 2016).</li><li><a class="nounderline abstract_t">Hotham J, Cannings-John R, Moore L, et al. Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents. Br J Psychiatry 2023; 223:478.</a></li><li><a class="nounderline abstract_t">Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des 2014; 20:2186.</a></li><li><a class="nounderline abstract_t">Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry 2019; 76:426.</a></li><li><a class="nounderline abstract_t">Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull 2016; 42:1262.</a></li><li class="breakAll">Bright Futures/American Academy of Pediatrics. Recommendations for Preventive Pediatric Health Care - Periodicity Schedule. https://www.aap.org/en/practice-management/care-delivery-approaches/periodicity-schedule/ (Accessed on September 01, 2023).</li><li class="breakAll">Adolescence. In: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd ed, Hagan JF, Shaw JS, Duncan PM (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2008. p.515.</li><li class="breakAll">Promoting Mental Health. In: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd ed, Hagan JF, Shaw JS, Duncan PM (Eds), American Academy of Pediatrics, Elk Grove Village, 2008. p.77.</li><li><a class="nounderline abstract_t">Knight JR, Sherritt L, Shrier LA, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med 2002; 156:607.</a></li><li class="breakAll">About the CRAFFT. https://crafft.org/about-the-crafft/ (Accessed on January 27, 2023).</li><li><a class="nounderline abstract_t">COMMITTEE ON SUBSTANCE USE AND PREVENTION. Substance Use Screening, Brief Intervention, and Referral to Treatment. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Levy S, Siqueira LM, Committee on Substance Abuse, et al. Testing for drugs of abuse in children and adolescents. Pediatrics 2014; 133:e1798.</a></li><li><a class="nounderline abstract_t">Levy S, Weitzman ER, Marin AC, et al. Sensitivity and specificity of S2BI for identifying alcohol and cannabis use disorders among adolescents presenting for primary care. Subst Abus 2021; 42:388.</a></li><li><a class="nounderline abstract_t">Kelly SM, Gryczynski J, Mitchell SG, et al. Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use. Pediatrics 2014; 133:819.</a></li><li class="breakAll">National Institute on Alcohol and Alcoholism (NIAAA, 2014). Alcohol Screening and Brief Intervention for Youth: A Practitioner’s Guide. http://pubs.niaaa.nih.gov/publications/Practitioner/YouthGuide/YouthGuide.pdf (Accessed on October 21, 2015).</li><li><a class="nounderline abstract_t">Winters KC, Kaminer Y. Screening and assessing adolescent substance use disorders in clinical populations. J Am Acad Child Adolesc Psychiatry 2008; 47:740.</a></li><li><a class="nounderline abstract_t">Martino S, Grilo CM, Fehon DC. Development of the drug abuse screening test for adolescents (DAST-A). Addict Behav 2000; 25:57.</a></li><li><a class="nounderline abstract_t">Tarter RE. Evaluation and treatment of adolescent substance abuse: a decision tree method. Am J Drug Alcohol Abuse 1990; 16:1.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li></ol></div><div id="topicVersionRevision">Topic 101699 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://monitoringthefuture.org/wp-content/uploads/2022/12/mtf2022.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Monitoring the Future national survey results on drug use, 1975–2022: Secondary school students. Monitoring the Future Monograph Series. Ann Arbor, MI: Institute for Social Research, University of Michigan. https://monitoringthefuture.org/wp-content/uploads/2022/12/mtf2022.pdf (Accessed on September 12, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832260" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The natural history of drug use from adolescence to the mid-thirties in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832260" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The natural history of drug use from adolescence to the mid-thirties in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832260" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The natural history of drug use from adolescence to the mid-thirties in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832260" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural history of drug use from adolescence to the mid-thirties in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832260" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The natural history of drug use from adolescence to the mid-thirties in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32871506" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196794" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Associations between solitary drinking and increased alcohol consumption, alcohol problems, and drinking to cope motives in adolescents and young adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196794" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Associations between solitary drinking and increased alcohol consumption, alcohol problems, and drinking to cope motives in adolescents and young adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196794" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Associations between solitary drinking and increased alcohol consumption, alcohol problems, and drinking to cope motives in adolescents and young adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474107" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use and abuse of alcohol and illicit drugs in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474107" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use and abuse of alcohol and illicit drugs in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474107" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use and abuse of alcohol and illicit drugs in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145178" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437756" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adolescent Opioid Misuse Attributable to Adverse Childhood Experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437756" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adolescent Opioid Misuse Attributable to Adverse Childhood Experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33410876" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33369615" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence and Childhood Precursors of Opioid Use in the Early Decades of Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648966" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comorbid psychopathology in adolescents and young adults treated for substance use disorders: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472299" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855043" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959686" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adolescent substance use disorder during the early stages of bipolar disorder: a prospective high-risk study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306791" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adolescent alcohol use, suicidal ideation, and suicide attempts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744443" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The risk of adolescent suicide across patterns of drug use: a nationally representative study of high school students in the United States from 1999 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744443" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The risk of adolescent suicide across patterns of drug use: a nationally representative study of high school students in the United States from 1999 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209385" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157785" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : What is the impact of comorbid depression on adolescent substance abuse treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519825" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093770" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genetically informative research on adolescent substance use: methods, findings, and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837255" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adverse health effects of non-medical cannabis use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837255" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Adverse health effects of non-medical cannabis use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11775078" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Age at onset of alcohol use and DSM-IV alcohol abuse and dependence: a 12-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Study-Adolescent Supplement (NCS-A)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728070" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ten-year prospective study of public health problems associated with early drinking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Substance use trajectories from early adolescence to emerging adulthood: A comparison of smoking, binge drinking, and marijuana use</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200273" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Binge drinking and associated health risk behaviors among high school students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200273" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Binge drinking and associated health risk behaviors among high school students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37485911" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23829363" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of cannabis on the adolescent brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30758486" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884547" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884547" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884547" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884547" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038895" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Validity of the CRAFFT substance abuse screening test among adolescent clinic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038895" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Validity of the CRAFFT substance abuse screening test among adolescent clinic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325638" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Substance Use Screening, Brief Intervention, and Referral to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864184" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Testing for drugs of abuse in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32814009" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sensitivity and specificity of S2BI for identifying alcohol and cannabis use disorders among adolescents presenting for primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753528" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753528" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574399" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Screening and assessing adolescent substance use disorders in clinical populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708319" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Development of the drug abuse screening test for adolescents (DAST-A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2330931" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation and treatment of adolescent substance abuse: a decision tree method.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
